Strategies focused on inhibiting oncogenic proteins in NSCLC, such as anaplastic lymphoma kinase (ALK), epidermal growth factor receptor (EGFR), c-ros oncogene 1 (ROS1), and v-raf murine sarcoma viral oncogene homolog B1 (BRAF), have been generated and therapies against these proteins have shown promise in combating NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.